In short
Clinical trials are studying Ifosfamide in several cancer types, especially sarcomas, lymphomas, leukemia, germ cell tumors, and neuroblastoma. These studies look at how well treatment works, how safe it is, and which patient groups may benefit most. Many trials compare Ifosfamide-based regimens with other treatments or test it in combinations.
Key points
- Clinical trials investigating Ifosfamide are being done in many cancer types, with the strongest focus on Ewing sarcoma, lymphomas, leukemia, germ cell tumors, and soft tissue sarcomas. The studies include Phase 1 through Phase 4, so they range from dose-finding and safety work to larger comparisons of treatment strategies. Many trials include children, adolescents, young adults, or adults with high-risk, relapsed, refractory, or newly diagnosed disease. Ifosfamide is usually tested as part of a combination treatment rather than by itself. The main study goals include event-free survival, disease-free survival, overall survival, response rate, and safety. Several trials also compare different treatment plans to see which one gives better control of the cancer.
Overview of Ifosfamide trials
These studies are testing Ifosfamide in different cancer treatment plans, mostly as part of combination therapy. The trial data show a wide range of goals, including finding the best dose, checking safety, and comparing how well treatment works against standard care or other regimens.
Cancer types being studied
Ifosfamide is being studied in trials for Ewing sarcoma, soft tissue sarcoma, osteosarcoma, lymphoma, leukemia, germ cell tumors, neuroblastoma, and penile squamous cell carcinoma. Some studies focus on newly diagnosed disease, while others include relapsed, refractory, recurrent, or high-risk disease.
Trial phases and study designs
The trial set includes Phase 1, Phase 2, Phase 3, and Phase 4 studies. Phase 1 trials in the data mainly look at dose-finding, safety, and tolerability, while later phases focus more on treatment benefit and comparison with standard regimens.
Most of the studies are interventional, which means the research team gives a treatment and then measures the results. Several trials are randomized, meaning patients are assigned by chance to different treatment groups, so the treatments can be compared fairly.
Who may take part
Eligibility depends on the trial and the cancer being studied. Some trials include children and adolescents, some include young adults, and some include adults only.
- Children and adolescents: Several leukemia, lymphoma, neuroblastoma, and sarcoma trials are designed for younger patients.
- Adults: Some lymphoma, sarcoma, and germ cell tumor studies are aimed at adults with relapsed, refractory, or advanced disease.
- High-risk disease: Many studies select patients with a higher chance of relapse or poor outcome, such as high-risk Ewing sarcoma or high-risk osteosarcoma.
- Relapsed or refractory disease: Some trials include people whose cancer came back or did not respond well to earlier treatment.
Main endpoints being measured
The most common endpoint is event-free survival, which means the time before a cancer-related event happens, such as relapse, progression, second cancer, or death. Other common endpoints are disease-free survival, overall survival, and objective response rate.
Some studies also measure treatment safety, including adverse effects, serious adverse effects, and dose-limiting toxicities, which are side effects that stop a dose from being increased further. In a few trials, researchers also look at special outcomes such as acute skin toxicity during radiotherapy, immune reconstitution, histological response, or complete metabolic response.
Selected trial examples
In the iEuroEwing trial, researchers are studying treatment optimization for people with Ewing sarcoma, including standard-risk, high-risk, and disseminated disease groups. The main goals include improving event-free survival and testing maintenance treatment added to standard chemotherapy.
In the AIEOP-BFM ALL 2017 trial, children and adolescents with acute lymphoblastic leukemia are being studied in several randomized questions, including whether extra therapy can improve event-free survival or disease-free survival in different risk groups. This trial also measures non-response, relapse, second malignancy, death, and in one part, immune recovery.
In the rEECur trial, patients with recurrent or primary refractory Ewing sarcoma are being compared across different chemotherapy regimens to find the best balance of efficacy, toxicity, and acceptability. The main endpoint is event-free survival time.
In the high-risk osteosarcoma study, patients aged 2 to 50 years are being treated with post-operative chemotherapy plus mifamurtide, and the main goal is to improve event-free survival. The study measures relapse, progression, second malignancy, and death as events.
In several lymphoma trials, Ifosfamide is part of salvage or combination treatment for relapsed or refractory disease, with outcomes such as response rate, progression-free survival, and event-free survival. These studies include both adult and pediatric populations.
What these trials mean for patients
For patients, these trials are trying to answer practical questions: which treatment works best, which treatment is safer, and which treatment gives the longest control of the cancer. Because the studies are different, a person may be eligible for one trial but not another based on age, diagnosis, disease risk, and how the cancer responded to earlier treatment. The trial data show that Ifosfamide is mainly being used as one part of a larger cancer treatment plan, not as a stand-alone study drug.